Risk of haemorrhagic stroke in patients with oral anticoagulation compared with the general population

Journal of Internal Medicine

Volumn 254, Issue 5, 2003, Pages 434-438

  Sjalander A ^a   Engstrom G ^a   Berntorp, E ^a   Svensson, P ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Haemorrhagic stroke; Oral anticoagulation; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; COHORT ANALYSIS; CONTROLLED STUDY; EPIDURAL HEMATOMA; FATALITY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; REGISTER; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; STROKE; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; SWEDEN;

EID: 0242351842     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2003.01209.x     Document Type: Article

References (23)

1. Johnsson H. Anticoagulant therapy can be safer: an active follow-up and written care programs reduce the number of complications. Läkartidningen 1999; 96: 3388-90 [in Swedish].
2. Palareti G, Leali N, Coccheri S et al. Bleeding complications of oral anticoagulant treatment: and inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: 423-8.
3. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687-91.
4. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994; 343: 687-91.
5. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin or both after myocardial infarction. N Engl J Med 2002; 347: 969-74.
6. Engström G, Jerntorp I, Pessah-Rasmussen H, Hedblad B, Berglund G, Janzon L. Geographical distribution of stroke incidence within an urban population. Relationships to socioeconomic circumstances and prevalence of cardiovascular risk factors. Stroke 2001; 32: 1098-103.
7. Franke CL, de Jonge J, van Swieten JC, Op de Coul AAW, van Gijn J. Intracerebral hematomas during anticoagulant treatment. Stroke 1990; 21: 726-30.
8. Wintzen AR, de Jonge H, Loeliger EA, Bots GTAM. The risk of intracerebral hemorrhage during oral anticoagulant treatment: a population study. Ann Neurol 1984; 16: 553-8.
9. Ericsson SE, Link H. Evaluation of anticoagulants in patients with cerebral infarction with slight to moderate neurological deficit. Acta Neurol Scand 1983; 68: 96-106.
10. Odén A, Fahlén M. Oral anticoagulation and risk of death: a medical record linkage study BMJ 2002; 325: 1073-5.
11. van Walraven C, Hart RG, Singer DE et al. Oral anticoagulation vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002; 288: 2441-8.
12. Fogelholm R, Eskola K, Kiminkinen T, Kunnamo I. Anticoagulant treatment as a risk factor for primary intracerebral hemorrhage. J Neur Neurosurg 1992; 55: 1121-4.
13. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage: facts and hypotheses. Stroke 1995; 26: 1471-7.
14. Neau JP, Couderq C, Ingrand P, Blanchon P, Gil R. Intracranial hemorrhage and oral anticoagulant treatment. Cerebrovasc Dis 2001; 11: 195-200.
15. Sjöblom L, Hårdemark HG, Lindgren A et al. Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy. A Swedish multicenter study. Stroke 2001; 32: 2567-74.
16. Hutten BA, Prins MH. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism (Cochrane Review). In: The Cochrane Library. Issue 2, 2003. Oxford: Update Software.
17. Segal JB, McNamara RL, Miller MR et al. Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter (Cochrane Review). In: The Cochrane Library, Issue 2. 2003. Oxford: Update Software.
18. Cannegieter SC, Rosendaal FR, Briët E. Thromboembolic and bleeding complications in patients with mechanical heart valve protheses. Circulation 1994; 89: 635-41.
19. Merlo J, Lindblad U, Pessah-Rasmussen H et al. Comparison of different procedures to identify probable cases of myocardial infarction and stroke in two Swedish prospective cohort studies using local and national routine registers. Eur J Epidemiol 2000; 16: 235-43.
20. August P, Oparil S. Hypertension in women. J Clin Endocrinol Metab 1999; 84: 1862-6.
21. Giardina EG. Heart disease in women. Int J Fertil 2000; 45: 350-7.
22. Hendricks AS, Goodman B, Stein JH, Carnes M. Gender differences in acute myocardial infarction: the University of Wisconsin experience. WMJ 1999; 98: 30-3.
23. Eriksson H, Wåhlander K, Lundström T, Billing Clason S, Schulman S. Extended secondary prevention with the oral direct thrombin inhibitor Ximegalatran for 18 months after 6 months of anticoagulation in patients with venous thromboembolism: a randomised, placebo-controlled trial. Blood 2002; 100: 81a (abstract no. 297).